



IntegraDose™
Compounding Services

Certificate of Manufacture / Analysis

Certificate ID: 10932

Drug Product: Cefazolin 2 Gram/20 mL, Syringe for Injection			
Batch/Lot ID: 20220204CEF-1		NDC: 71139-7087-1	
Strength: <u>2 gram</u>	Container: <u>30 mL syringe</u>	Volume (Amount): <u>20 mL</u>	
Production Date: <u>02/04/2022</u>		Expiration Date: <u>03/21/2022</u>	
Storage: Refrigerated Temperature, 2°C - 8°C			
Testing Results			
Test/Parameter	Specification	Result	Date of Analysis
Cefazolin Potency / ID	90.0 % - 115.0 % / Positive	97.8* % / Positive	02/14/2022
Endotoxin (USP <85>)	≤ 15.0 EU/mL	< 0.50 EU/mL	02/14/2022
Sterility (USP <71>)	Negative Growth (at 14 Days)	Negative	02/18/2022**
Visual Inspection	NMT 0 Units Non-Conforming	Pass	02/04/2022
Filter Integrity	Pressure > 55 psi	NA	NA
*Comments: Average potency reported if >1 unit sampled. All units within required specification.			
**Confirmed batch on test - no turbidity to date. Final results are pending a 14 day read.			
Statement of Conformity: <i>IntegraDose Compounding Services, LLC certifies that the above product has successfully passed all testing as per the applicable test specifications. All products manufactured under IntegraDose's Quality System meet the regulatory requirements for 503B Outsourcing Facilities (21 USC 353b: Outsourcing facilities and the FDA Current Good Manufacturing Practice – Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act) and all other applicable internal Quality requirements. All products are manufactured with validated processes to current specifications and are inspected to ensure they meet quality requirements.</i>			

Certificate Preparation Date: 02/18/2022

By/Date: _____

Quality Review/Date: _____

719 Kasota Ave Southeast, Minneapolis, MN 55414

integradose.org

